Chinese pharmaceutical group WuXi AppTec has said it is lobbying hard in Washington against a proposed bill that threatens its business in the US, where it generates 65 per cent of its revenues.“The company has been actively working together with its advisers to set the record straight and advocate for changes to the proposed legislation,” Edward Hu, vice-chair and chief investment officer, said in an analysts’ call on Tuesday following the release of full-year results.
中國醫藥集團藥明康德(WuXi AppTec)表示，其正在華盛頓努力游說，反對一項將威脅其美國業務的擬議法案。該公司65%的收入來自美國。
您已閱讀15%（543字），剩余85%（2975字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。